TransDigm: Culture & Pricing
Former President at TransDigm
inpractise.com/articles/transdigm-culture-and-pricing
TransDigm: Culture & Pricing(August 31, 2024)
Former President at TransDigm
Interview Transcript
This is a snippet of the transcript, sign up to read more.
And the new product development, how did TransDigm evaluate that?
That was probably their weakest link and less of a focus. They left that up to the business. They measured the number of prototypes made, which might make sense for some businesses. They would look at sales and split it between recurring OE business or new business. There were some definitions. If you won a new program, the sales in that program for the first two or three years were considered new business. After that, it became recurring business. They would measure last year's sales under new business and this year's sales under new business, and it was supposed to grow to support the bottom line.
This is a snippet of the transcript, sign up to read more.
Related Content
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.